• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PENUMBRA, INC. PENUMBRA SYSTEM ACE 60 REPERFUSION CATHETER; NRY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PENUMBRA, INC. PENUMBRA SYSTEM ACE 60 REPERFUSION CATHETER; NRY Back to Search Results
Catalog Number 5MAXACE132
Medical Device Problem Codes Fracture (1260); Physical Resistance/Sticking (4012)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 01/12/2024
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
This device is available for return.A follow up mdr will be submitted upon completion of the device investigation.H3 other text : placeholder.
 
Event or Problem Description
The patient was undergoing a medical procedure in the m1 segment of the middle cerebral artery (mca) using a penumbra system ace 60 reperfusion catheter (ace60), a neuron max 6f 088 long sheath (neuron max), and a guidewire.It should be noted that the patient''s anatomy was tortuous.During the procedure, the physician successfully completed two to three passes in the target location using the ace60.While advancing the ace60 during the next pass, the physician experienced resistance and subsequently found that the proximal end of the ace60 was fractured.Therefore, the ace60 was no longer used in the procedure.The procedure was completed using a new ace60 and the same neuron max.There was no report of an adverse effect to the patient.
 
Additional Manufacturer Narrative
Evaluation of the returned ace60 confirmed that the catheter was fractured on the proximal end underneath the strain relief.If the ace60 is advanced against resistance, damage such as a kink and subsequent fracture may occur.During decontamination, a leak was observed coming from underneath the strain relief.Penumbra catheters are inspected during in-process inspection and during quality inspection after manufacturing.The manufacturing records for this lot were reviewed and did not reveal any outstanding discrepancies, design, or quality concerns.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PENUMBRA SYSTEM ACE 60 REPERFUSION CATHETER
Common Device Name
NRY
Manufacturer (Section D)
PENUMBRA, INC.
one penumbra place
alameda CA 94502
Manufacturer Contact
veronica farris
one penumbra place
alameda, CA 94502
5107483200
MDR Report Key18758183
Report Number3005168196-2024-00058
Device Sequence Number3703416
Product Code NRY
UDI-Device Identifier00814548017426
UDI-Public814548017426
Combination Product (Y/N)N
Initial Reporter CountryCH
PMA/510(K) Number
K160449
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,Health Professional,Distributor
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 03/20/2024
Report Date (Section F) 01/01/2005
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date11/09/2025
Device Catalogue Number5MAXACE132
Device Lot NumberF00004098
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Date Report to Manufacturer01/10/2005
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 01/24/2024
Supplement Date Received by Manufacturer03/15/2024
Initial Report FDA Received Date02/22/2024
Supplement Report FDA Received Date03/20/2024
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured11/10/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient Age62 YR
Patient SexMale
Date Report Sent to FDA01/01/2005
-
-